|09/22/17||James Noble, Adaptimmune CEO, to Participate in Upcoming Leerink Partners Roundtable Series: Rare Disease & Immuno-Oncology|
|PHILADELPHIA and OXFORD, U.K., Sept. 22, 2017 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, today announced that James Noble, Adaptimmune’s Chief Executive Officer, will participate in the upcoming Leerink Partners Roundtable Series: Rare Disease and Immuno-oncology on Thursday, September 28, 2017 at 10:30 AM EDT (3:30 PM BST) in Holmes I/II at the Lotte New York Palace Hotel.
The conference will be webcast live for investors thr... |
|09/07/17||GSK Exercises Option over SPEAR T-cell Therapy Program Targeting NY-ESO|
|PHILADELPHIA and OXFORD, United Kingdom, Sept. 07, 2017 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, today announced that GlaxoSmithKline plc (LSE:GSK) (NYSE:GSK) has exercised its option under a collaboration and license agreement signed in 2014 to exclusively license the right to research, develop, and commercialize Adaptimmune’s NY-ESO SPEAR T-cell therapy program. Further details will be provided in a conference call scheduled ... |
|08/30/17||Adaptimmune to Present at Upcoming CAR-TCR Summit; CEO James Noble to be a Keynote Speaker|
|PHILADELPHIA and OXFORD, U.K., Aug. 30, 2017 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in the use of TCR engineered T-cell therapy to treat cancer, today announced its participation in the CAR-TCR Summit in Boston on Tuesday, September 5, and Wednesday, September 6 at the Seaport Hotel & World Trade Center; One Seaport Lane, Boston, MA 02210.
The CAR-TCR summit highlights leaders in the CAR-T and TCR space to create a platform for cell immunotherapy expert... |
|08/03/17||Adaptimmune Reports Second Quarter 2017 Financial Results|
|– A registered direct offering in April combined with a public offering in March raised net proceeds of $103.2 million; operations funded through to late 2019 –
– Enrolling 9 clinical studies with NY-ESO as well as our wholly-owned assets (MAGE-A4, MAGE-A10, and AFP) across 12 different tumor indications –
– On track for initial data from our wholly-owned assets in 2017 and 2018 –
– NY-ESO data presented at the Annual American Society of Clinical Oncology Meeting (ASCO) c... |